白血病干/祖细胞及靶向治疗研究进展  

Leukemia Stem/Progenitor Cells and Target Therapy for Leukemia——Review

作　　者：王钿钿[1] 陈宝安[1] 

机构地区：[1]东南大学医学院中大医院血液科,江苏南京210009

出　　处：《中国实验血液学杂志》2010年第6期1654-1658,共5页Journal of Experimental Hematology

摘　　要：人类白血病是一种由造血干/祖细胞或祖细胞染色体变异或者渐进性改变的恶性克隆性疾病,耐药与复发是白血病治疗失败的两大主要原因。近年来对于白血病患者体白血病干/祖细胞(LSPC)的发现和研究,深入阐述了白血病的发生机制,并探索了针对LSPC的靶向治疗。本文简要介绍LSPC的分子生物学特性以及LSPC靶向治疗,诸如针对LSPC表面分子的靶向治疗,针对特殊分子调控机制的靶向治疗,针对干扰LSPC与骨髓微环境间相互作用的靶向治疗等的研究进展。Human leukemias are considered as clonal malignancies initiated at stage as early as hematopoietic stem/progenitor cells. The drug resistance and relapse are two major causes for treatment failure of leukemia. Recently, the discovery of leukemia stem/progenitor cells （LSPC） and subsequent research have provided a cue to elucidate the pathogenesis of leukemia and to explore the strategies of targeted therapy against LSPC. This review summarzes the molecular characteristics of LSPC and some research advances of therapy targeting LSPC including therapy targeting to surface molecules of LSPC, interference of interaction between LSPC and bone marrow microenviroment, regulation mechanims of some spacific moleculars and so on.

关 键 词：白血病 白血病干/祖细胞 靶向治疗 

分 类 号：R733.7[医药卫生—肿瘤] R730.5[医药卫生—临床医学]